A Phase 3 Study of Ketamine in Alcohol Use Disorder in United Kingdom

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 20 Oct 2023

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

06 Sep 2023 According to an Awakn Life Sciences media release, company is looking to initiate discussions in the near-term with the MHRA and NICE on development plan and market access in parallel to the executing the phase III.
06 Sep 2023 According to an Awakn Life Sciences media release, Awakn and its partners are expecting feedback in the coming months on the CTA, and subject to ethical and regulatory approval, first trial participants will be treated in late Q4 2023 or early Q1 2024.
06 Sep 2023 According to an Awakn Life Sciences media release, company has submitted the Clinical Trial Application for this trial and this trial will be delivered in the UK across ten UK National Health Service (NHS) sites.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com